The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Shares of Olympus Corp. (TYO:7733) regained more than 17 percent over the weekend after the Tokyo stock exchange indicated it might not de-list the world’s largest endoscope maker, brought low by a scheme to hide its losses with buyouts.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Robert Parkinson Jr., chairman & CEO of Baxter International (NYSE:BAX), added 20 percent to his paycheck total from last year by cashing in on stock options for the first time.
Parkinson, 60, who earned $11.5 million last year, netted $14.1 million last month after exercising the options and selling stock.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Becton Dickinson & Co. (NYSE:BDX) is at its lowest valuation since 1993, making it ripe for a buyout, after reporting dismal third-quarter results last week.
The company posted a 24 percent profit slide for the quarter Nov. 2, sending shares down 4.6 percent to a close of $72.60 that day.
Shares of Becton Dickinson (NYSE:BDX) slipped 4.4 percent today after the company announced a 24.4 percent profit slide and missed Wall Street’s expectations for its Q4 earnings.
BD posted profits of $300.0 million, or $1.36 per share, on sales of $2.05 billion for the three months ended Sept. 30. That compares with profits of $396.7 million, or $1.68 per share, on sales of $1.87 billion during the same period last year.
Shares of Becton Dickinson (NYSE:BDX) slipped 4.4 percent today after the company announced a 24.4 percent profit slide and missed Wall Street’s expectations for its Q4 earnings.
BD posted profits of $300.0 million, or $1.36 per share, on sales of $2.05 billion for the three months ended Sept. 30. That compares with profits of $396.7 million, or $1.68 per share, on sales of $1.87 billion during the same period last year.
The U.S. Supreme court refused to hear an appeal by Stryker Corp. (NYSE:SYK) in a product liability lawsuit filed over its recalled Trident hip implant.
AtriCure Inc. (NSDQ:ATRC) could be poised for a buyout over the next year to 18 months, according to Canaccord Genuity analyst Jason Mills.
Medical device investment deals got fatter and less frequent during the second quarter, as the value of deals grew 9 percent but their number slid 17 percent, according to PricewaterhouseCoopers.
Backers pumped $841 million into med-tech firms with 90 deals during the three months ended June 30, according to the consulting firm’s MoneyTree report. That’s up 26 percent and 3 percent, respectively, over the first quarter. The industry’s share of the venture capital cash spend on life sciences last quarter ticked down to 40 percent, however, compared with Q1 numbers.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
